natgillin/translations-raw huggingface dataset:
The use of Descovy in children aged 11 years or under has not yet been studied. 
Uporabe zdravila Descovy pri otrocih, starih 11 let ali manj, še niso preučili.
If Descovy is stopped for any reason, speak to your doctor before you restart taking Descovy tablets. 
Če zaradi katerega koli razloga prenehate jemati zdravilo Descovy, se pogovorite s svojim zdravnikom, preden začnete ponovno jemati tablete zdravila Descovy.
7 Study conducted with additional voxilaprevir 100 mg to achieve voxilaprevir exposurers expected in HCV-infected patients. 
7 Študija je bila opravljena z dodatnim voksilaprevirjem 100 mg za doseganje izpostavljenosti voksilaprevirju, pričakovane pri bolnikih, okuženih s HCV.
There are no adequate and well-controlled studies of Descovy or its components in pregnant women. 
Ni ustreznih, dobro kontroliranih študij z zdravilom Descovy ali njegovimi učinkovinami pri nosečnicah.
Ethinylestradiol: 
etinilestradiol:
If you have hepatitis B liver problems may become worse after you stop taking Descovy. 
Če imate hepatitis B, se lahko težave z jetri poslabšajo, ko prenehate jemati zdravilo Descovy.
Iron oxide black (E172) 
smukec črni železov oksid (E172)
Once you start taking Descovy, look out for: 
Ko začnete jemati zdravilo Descovy, bodite pozorni na:
It is recommended that you do not breast-feed to avoid passing the virus to the baby through breast milk. 
Priporočljivo je, da ne dojite, da s tem preprečite prenos virusa z mlekom na dojenčka.
At baseline, median eGFR was 56 mL/min, and 33% of patients had an eGFR from 30 to 49 mL/min. 
Na začetku je bila mediana eGFR 56 ml/min, 33 % bolnikov pa je imelo vrednost eGFR od 30 do 49 ml/min.
Ex vivo binding of tenofovir alafenamide to human plasma proteins in samples collected during clinical studies was approximately 80%. 
Ex vivo vezava tenofoviralafenamida na humane plazemske proteine v vzorcih, odvzetih med kliničnimi študijami, je bila približno 80 %.
In some patients with advanced HIV infection (AIDS) and who have had opportunistic infections in the past (infections that occur in people with a weak immune system), signs and symptoms of inflammation from previous infections may occur soon after antiretroviral treatment is started. 
Pri nekaterih bolnikih z napredovalo okužbo s HIV (AIDSom) in tistih, ki so imeli oportunistične okužbe v preteklosti (okužbe, ki se pojavijo pri ljudeh z oslabljenim imunskim sistemom), se lahko znaki in simptomi vnetja zaradi prejšnjih okužb pojavijo kmalu po začetku protiretrovirusnega zdravljenja.
Pharmacotherapeutic group: Antiviral for systemic use; antivirals for treatment of HIV infections, combinations. 
Farmakoterapevtska skupina: zdravilo za sistemsko zdravljenje virusnih infekcij, zdravila za zdravljenje infekcij s HIV, kombinacije.
The European Medicines Agency has deferred the obligation to submit the results of studies with Descovy in one or more subsets of the paediatric population in the treatment of HIV-1 infection (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je začasno odložila zahtevo za predložitev rezultatov študij z zdravilom Descovy za eno ali več podskupin pediatrične populacije za zdravljenje okužbe z virusom HIV-1 (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
Adolescents 12 years of age and older, who weigh at least 35 kg: one tablet each day with or without food Do not chew, crush or split the tablet. 
Mladostniki, stari 12 let ali več, s telesno maso vsaj 35 kg: ena tableta vsak dan s hrano ali brez nje Tablete ne žvečite, drobite in ne delite.
Tipranavir/ritonavir results in P-gp induction. 
Tipranavir/ritonavir ima za posledico indukcijo P-gp.
Interaction not studied with either of the components of Descovy. 
Interakcij niso preučili z nobeno od učinkovin zdravila Descovy.
No data are available to make dose recommendations in children less than 18 years with end stage renal disease. 
Ni podatkov za dajanje priporočil o odmerjanju pri otrocih, starih manj kot 18 let s končno ledvično odpovedjo.
2 This adverse reaction was not observed in the clinical studies of F/TAF-containing products but identified from clinical studies or post-marketing experience for emtricitabine when used with other antiretrovirals. 
2 Tega neželenega učinka niso opazili v kliničnih študijah za zdravila, ki vsebujejo F/TAF, temveč je bil opredeljen v kliničnih študijah ali izkušnjah v obdobju trženja za emtricitabin pri uporabi z drugimi protiretrovirusnimi zdravili.
If you vomit less than 1 hour after taking Descovy, take another tablet. 
Če bruhate manj kot 1 uro po zaužitju zdravila Descovy, vzemite še eno tableto.
If you are on dialysis, take your daily dose of Descovy following completion of dialysis. 
Če ste na dializi, vzemite svoj dnevni odmerek zdravila Descovy po končani dializi.
The safety and efficacy of Descovy in patients co-infected with HIV-1 and hepatitis C virus (HCV) have not been established. 
Varnost in učinkovitost zdravila Descovy pri bolnikih s hkratno okužbo s HIV-1 in hepatitisa C (HCV) nista bili dokazani.
If you forget to take Descovy 
Če ste pozabili vzeti zdravilo Descovy
• antiviral medicines used to treat HIV: 
• zdravila za zdravljenje virusnih okužb, ki se uporabljajo za zdravljenje HIV:
Interactions between the components of Descovy and potential co-administered medicinal products are listed in Table 2 (increase is indicated as “↑”, decrease as “↓”, no change as “↔”). 
Interakcije med učinkovinami zdravila Descovy in možnimi sočasno uporabljenimi zdravili so navedene v preglednici 2 (povečanje je označeno z znakom “↑”, zmanjšanje z “↓”, brez spremembe z “↔”).
Some patients taking combination antiretroviral medicines such as Descovy may develop a bone disease called osteonecrosis (death of bone tissue caused by loss of blood supply to the bone). 
Pri nekaterih bolnikih, ki jemljejo kombinirana protiretrovirusna zdravila, kot je zdravilo Descovy, se lahko pojavi bolezen kosti, imenovana osteonekroza (odmiranje kostnega tkiva kot posledica pomanjkanja oskrbe kosti s krvjo).
Emtricitabine and tenofovir alafenamide demonstrated synergistic antiviral activity in cell culture. 
Emtricitabin in tenofoviralafenamid sta pokazala sinergijsko protivirusno aktivnost v celični kulturi.
No dose adjustment of sertraline is required. 
Odmerka sertralina ni treba prilagajati.
Missing data during window but on study drug 
V oknu podatki manjkajo, a uporablja študijsko zdravilo
Tenofovir is efficiently removed by haemodialysis with an extraction coefficient of approximately 54%. 
Tenofovir se učinkovito odstrani s hemodializo s koeficientom estrakcije približno 54 %.
The adverse reactions in Table 3 are listed by system organ class and frequency. 
Neželeni učinki v preglednici 3 so našteti po organskih sistemih in pogostnosti.
Frequencies are defined as follows: very common (≥ 1/10), common (≥ 1/100 to < 1/10) and uncommon (≥ 1/1,000 to 
Pogostnost je definirana kot sledi: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10) in občasni (≥ 1/1.000 do Preglednica 3: Seznam neželenih učinkov v obliki preglednice1 Pogostnost
Patients were stratified by the class of the third agent in their prior treatment regimen. 
Bolniki so bili stratificirani glede na razred tretjega zdravila v predhodnem režimu zdravljenja.
The pharmacokinetics of emtricitabine have not been studied in subjects with hepatic impairment; however, emtricitabine is not significantly metabolised by liver enzymes, so the impact of liver impairment should be limited. 
Farmakokinetičnih lastnosti emtricitabina pri preizkušancih z jetrno okvaro niso proučevali, vendar jetrni encimi emtricitabina ne presnavljajo v pomembnem obsegu, zato je vpliv jetrne okvare verjetno omejen.
The interactions described are based on studies conducted with Descovy, or the components of Descovy as individual agents and/or in combination, or are potential drug-drug interactions that may occur with Descovy. 
Opisane interakcije temeljijo na študijah, izvedenih z zdravilom Descovy ali z učinkovinami zdravila Descovy, kot posamičnimi učinkovinami in/ali v kombinaciji, ali pa je možno medsebojno delovanje, ki se lahko pojavi z zdravilom Descovy.
Changes in measures of renal function 
Spremembe v meritvah delovanja ledvic
Most HIV-1 isolates from patients in both treatment groups who developed resistance mutations to elvitegravir in integrase also developed resistance mutations to emtricitabine in RT. 
Pri večini izolatov HIV-1 bolnikov v obeh skupinah zdravljenja, pri katerih so se razvile mutacije, povezane z rezistenco na elvitegravir v integrazi, so se razvile tudi mutacije proti emtricitabinu v RT.
Medicinal products that strongly affect P-gp and BCRP activity may lead to changes in tenofovir alafenamide absorption. 
Zdravila, ki močno vplivajo na aktivnost BCRP in P-gp lahko povzročijo spremembe v absorpciji tenofoviralafenamida.
What you need to know before you take Descovy Do not take Descovy: 
Kaj morate vedeti, preden boste vzeli zdravilo Descovy Ne jemljite zdravila Descovy:
1 When doses are provided, they are the doses used in clinical drug-drug interaction studies. 
1 Kjer so navedeni odmerki, so to odmerki, ki so jih uporabljali v kliničnih študijah medsebojnega delovanja zdravil.
The safety of emtricitabine and tenofovir alafenamide has not been established in these patients. 
Varnosti emtricitabina in tenofoviralafenamida pri teh bolnikih niso dokazali.
No dose adjustment of midazolam is required. 
Odmerka midazolama ni treba prilagajati.
a n = 24 adolescents (GS-US-292-0106); n = 19 adults (GS-US-292-0102) b n = 23 adolescents (GS-US-292-0106, population PK analysis) c n = 539 (TAF) or 841 (TFV) adults (GS-US-292-0111 and GS-US-292-0104, population PK analysis) 
a n = 24 mladostnikov (GS-US-292-0106); n = 19 odraslih (GS-US-292-0102) b n = 23 mladostnikov (GS-US-292-0106, populacijska FK-analiza) c n = 539 (TAF) ali 841 (TFV) odraslih (GS-US-292-0111 in GS-US-292-0104, populacijska FK-analiza)
While taking Descovy you may still develop infections or other illnesses associated with HIV infection. 
Med jemanjem zdravila Descovy se lahko pojavijo okužbe ali druge bolezni, povezane z okužbo z virusom HIV.
Cmax, Cmin2 
AUC, Cmax, Cmin2
Therefore, Descovy should not be used during breast-feeding. 
Zato se zdravilo Descovy med dojenjem ne sme uporabljati.
No dose adjustment of Descovy is required in elderly patients (see sections 5.1 and 5.2). 
Odmerka zdravila Descovy pri starejših bolnikih ni treba prilagoditi (glejte poglavji 5.1 in 5.2).
Pooled treatment outcomes at 48 and 144 weeks are shown in Table 4. 
Združeni izidi zdravljenja v 48. in 144. tednu so prikazani v preglednici 4.
What Descovy is and what it is used for What you need to know before you take Descovy How to take Descovy 
Kaj je zdravilo Descovy in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Descovy Kako jemati zdravilo Descovy Možni neželeni učinki
• Use effective contraception while taking Descovy. 
• Med jemanjem zdravila Descovy morate uporabljati učinkovito kontracepcijo.
Maraviroc Nevirapine Raltegravir 
maravirok nevirapin raltegravir
The safety and efficacy of Descovy in children younger than 12 years of age, or weighing < 35 kg, have not yet been established. 
Pediatrična populacija Varnost in učinkovitost zdravila Descovy pri otrocih, mlajših od 12 let, ali s telesno maso < 35 kg, še nista bili dokazani.
The mean steady state plasma trough concentration at 24 hours post-dose was equal to or greater than the mean in vitro IC90 value for anti-HIV-1 activity. 
Povprečna plazemska koncentracija v stanju dinamičnega ravnovesja 24 ur po odmerjanju pred naslednjim odmerkom je bila enaka ali večja kot povprečna vrednost IC90 in vitro za aktivnost proti-HIV-1.
Descovy comes in bottles of 30 tablets (with a silica gel desiccant that must be kept in the bottle to help protect your tablets). 
Zdravilo Descovy je na voljo v plastenkah po 30 tablet (s silikagelskim sušilnim sredstvom, ki mora ostati v vsebniku zaradi zaščite tablet).
Then take the next dose as usual. 
Nato vzemite naslednji odmerek ob svojem običajnem času.
There have been reports of a high rate of virological failure and of emergence of resistance at an early stage when tenofovir disoproxil was combined with lamivudine and abacavir as well as with lamivudine and didanosine as a once daily regimen. 
Poročali so o velikem deležu virološkega neuspeha in pojava rezistence v zgodnji fazi, ko so dizoproksiltenofovirat kombinirali z lamivudinom in abakavirjem ter lamivudinom in didanozinom z režimom odmerjanja enkrat na dan.
Other medicines and Descovy Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. 
Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
E/C/F/TAF = elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate FTC = emtricitabine; TAF = tenofovir alafenamide fumarate; TFV = tenofovir N/A = not applicable 
E/C/F/TAF = elvitegravir/kobicistat/emtricitabin/tenofoviralafenamidijev fumarat FTC = emtricitabin; TAF = tenofoviralafenamidijev fumarat; TFV = tenofovir n/v = ne velja
Relative to fasting conditions, the administration of tenofovir alafenamide with a high fat meal (~800 kcal, 50% fat) resulted in a decrease in tenofovir alafenamide Cmax (15-37%) and an increase in AUClast (17-77%). 
Relativno glede na pogoje na tešče je dajanje tenofoviralafenamida z obrokom z veliko vsebnostjo maščob (~ 800 kcal, 50 % maščobe) povzročilo zmanjšanje vrednost Cmax (15-37 %) in povečanje vrednost AUClast (17-77 %) za tenofoviralafenamid.
Dose Descovy according to the concomitant antiretroviral (see section 4.2). 
Zdravilo Descovy se odmerja v skladu s sočasno uporabljenimi protiretrovirusnimi zdravili (glejte poglavje 4.2).
The safety and efficacy of Descovy in patients with significant underlying liver disorders have not been established (see sections 4.2 and 5.2). 
Varnost in učinkovitost zdravila Descovy pri bolnikih s pomembnejšimi sočasnimi jetrnimi boleznimi nista bili dokazani (glejte poglavji 4.2 in 5.2).
Adults and adolescents aged 12 years and older, weighing at least 35 kg Descovy should be administered as shown in Table 1. 
Odrasli in mladostniki, stari 12 let in več, s telesno maso vsaj 35 kg Zdravilo Descovy je treba dajati, kot je prikazano v preglednici 1.
The biotransformation of emtricitabine includes oxidation of the thiol moiety to form the 3'-sulfoxide diastereomers (~9% of dose) and conjugation with glucuronic acid to form 2'-O-glucuronide (~4% of dose). 
Biotransformacija emtricitabina vključuje oksidacijo tiolnega dela molekule, pri čemer nastanejo 3'-sulfoksid diastereomere (~ 9 % odmerka) in konjugacijo z glukuronsko kislino, pri čemer nastane 2'-O-glukuronid (~ 4 % odmerka).
Renal excretion of intact tenofovir alafenamide is a minor pathway with < 1% of the dose eliminated in urine. 
Ledvično izločanje nespremenjenega tenofoviralafenamida je manj pomembna pot z < 1 % odmerka, izločenega v urinu.
In some patients with advanced liver disease or cirrhosis, stopping treatment may lead to worsening of hepatitis, which may be life-threatening. 
Pri nekaterih bolnikih z napredovalim obolenjem jeter ali cirozo prenehanje zdravljenja lahko povzroči poslabšanje hepatitisa, ki je lahko življenjsko nevarno.
• If you notice within 18 hours of the time you usually take Descovy, you must take the tablet as soon as possible. 
• Če to opazite v roku 18 ur od časa, ko zdravilo Descovy običajno vzamete, morate tableto vzeti čim prej.
On days of haemodialysis, Descovy should be administered after completion of haemodialysis treatment. 
Ob dneh hemodialize je treba zdravilo Descovy dati po koncu zdravljenja s hemodializo.
However, tenofovir disoproxil fumarate reduced the viability index and weight of pups in a peri-postnatal toxicity study at maternally toxic doses. 
Vendar pa je tenofoviralafenamidijev fumarat zmanjšal indeks viabilnosti in telesno maso mladičev v peri- in postnatalni študiji toksičnosti pri odmerkih, toksičnih za mater.
E/C/F/TAF demonstrated statistical superiority in achieving HIV-1 RNA < 50 copies/mL when compared to E/C/F/TDF at Week 144. 
Zdravilo E/C/F/TAF je izkazalo statistično superiornost pri doseganju HIV-1 RNA < 50 kopij/ml v primerjavi z E/C/F/TDF v 144. tednu.
Following administration of tenofovir alafenamide, plasma [14C]-radioactivity showed a time-dependent profile with tenofovir alafenamide as the most abundant species in the initial few hours and uric acid in the remaining period. 
Po dajanju tenofoviralafenamida je plazemska [14C]-radioaktivnost pokazala od časa odvisni profil, pri tem je bil tenofoviralafenamid najbolj zastopana vrsta radioaktivnosti v prvih nekaj urah in sečna kislina v preostalem obdobju.
Emtricitabine is rapidly and extensively absorbed following oral administration with peak plasma concentrations occurring at 1 to 2 hours post-dose. 
Emtricitabin se po peroralni uporabi hitro in obsežno absorbira z največjimi koncentracijami v plazmi od 1 do 2 uri po odmerjanju.
It is important not to miss a dose of Descovy. 
Pomembno je, da ne pozabite vzeti odmerka zdravila Descovy.
Treatment outcomes of Study GS-US-311-1089 through 48 and 96 weeks are presented in Table 6. 
Izidi zdravljenja v študiji GS-US-311-1089 do vključno 48. tedna in 96. tedna so predstavljeni v preglednici 6.
• herbal remedies used to treat depression and anxiety containing: St. John's wort (Hypericum perforatum) 
• zdravila rastlinskega izvora, ki se uporabljajo za zdravljenje depresije in tesnobe, ki vsebujejo: - šentjanževko (Hypericum perforatum)
b In both studies, patients were stratified by baseline HIV-1 RNA (≤ 100,000 copies/mL, > 100,000 copies/mL to ≤ 400,000 copies/mL, or > 400,000 copies/mL), by CD4+ cell count (< 50 cells/μL, 50-199 cells/μL, or ≥ 200 cells/μL), and by region (US or ex-US). 
b V obeh študijah so bili bolniki stratificirani glede na začetno vrednost HIV-1 RNA (≤ 100.000 kopij/ml, > 100.000 kopij/ml do ≤ 400.000 kopij/ml ali > 400.000 kopij/ml), po številu celic CD4+ (< 50 celic/μl, 50-199 celic/μl ali ≥ 200 celic/μl) in po regiji (ZDA ali zunaj ZDA).
The frequencies were derived from Phase 3 E/C/F/TAF clinical studies in 866 treatment-naïve adult patients through 144 weeks of treatment (GS-US-292-0104 and GS-US-292-0111). 
Pogostnosti so bile izpeljane iz kliničnih študij faze 3 z E/C/F/TAF pri 866 predhodno nezdravljenih odraslih bolnikih do vključno 144. tedna zdravljenja (GS-US-292-0104 in GS-US-292-0111).
Overall, 22% had baseline plasma HIV-1 RNA > 100,000 copies/mL. 
Celokupno je imelo 22 % začetno plazemsko HIV-1 RNA > 100.000 kopij/ml.
Table 2: Interactions between the individual components of Descovy and other medicinal products 
Preglednica 2: Interakcije med posameznimi učinkovinami zdravila Descovy in drugimi zdravili Učinkovine po terapevtskih področjih1
Descovy should be avoided in patients with estimated CrCl ≥ 15 mL/min and < 30 mL/min, or < 15 mL/min who are not on chronic haemodialysis, as the safety of Descovy has not been established in these populations. 
Zdravilu Descovy se je treba izogniti pri bolnikih z ocenjenim CrCl ≥ 15 ml/min in < 30 ml/min ali < 15 ml/min, ki niso na kronični hemodializi, saj varnosti zdravila Descovy pri teh populacijah niso dokazali.
Emtricitabine systemic exposure was unaffected when emtricitabine was administered with food. 
Dajanje emtricitabina s hrano ni vplivalo na sistemsko izpostavljenost emtricitabinu.
Descovy is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (HIV-1) (see sections 4.2 and 5.1). 
Zdravilo Descovy je indicirano v kombinaciji z drugimi protiretrovirusnimi učinkovinami za zdravljenje odraslih in mladostnikov (starih 12 let in več s telesno maso vsaj 35 kg), okuženih z virusom humane imunske pomanjkljivosti tipa 1 (HIV-1) (glejte poglavji 4.2 in 5.1).
Tenofovir alafenamide exposure is expected to decrease when tipranavir/ritonavir is used in combination with Descovy. 
Pričakuje se, da se bo izpostavljenost tenofoviralafenamidu pri uporabi tipranavirja/ritonavirja v kombinaciji z zdravilom Descovy zmanjšala.
Do not stop taking Descovy without talking to your doctor: see section 3, Do not stop taking Descovy. 
Ne prenehajte jemati zdravila Descovy, ne da bi se pogovorili z zdravnikom: glejte poglavje 3,
No dose adjustment of norgestimate/ethinylestradiol is required. 
Odmerka norgestimata/etinilestradiola ni treba prilagajati.
• If you notice 18 hours or more after the time you usually take Descovy, then do not take the missed dose. 
• Če to opazite po 18 urah ali več od časa, ko običajno vzamete zdravilo Descovy, pozabljenega odmerka ne vzemite.
102.4 (38.9)b 
102,4 (38,9)b n/v n/v
The safety profile in patients with mild to moderate renal impairment was similar to that in patients with normal renal function (see section 5.1). 
Varnostni profil zdravila Descovy pri bolnikih z blago do zmerno ledvično okvaro je bil podoben kot pri bolnikih z normalnim delovanjem ledvic (glejte poglavje 5.1).
Although kidney problems have not been observed with Descovy, there is a possibility that you may experience kidney problems when taking Descovy over a long period of time. 
Čeprav pri zdravilu Descovy niso opazili težav z ledvicami, obstaja možnost, da boste med dolgotrajnim jemanjem zdravila imeli težave z ledvicami.
The mean age was 58 years (range: 24-82), with 63 patients (26%) who were ≥ 65 years of age. 
Povprečna starost je bila 58 let (razpon: 24-82), s 63 bolniki (26 %), starimi ≥ 65 let.
There are no data available to make dosing recommendations for co-administration with other protease inhibitors. 
Ni podatkov za priporočila o odmerjanju pri sočasnem dajanju z drugimi zaviralci proteaze.
Darunavir, cobicistat and emtricitabine/tenofovir disoproxil fumarate (n = 50) 
Darunavir, kobicistat in emtricitabin/ dizoproksiltenofovirijev fumarat (n = 50)
Of the patients who were HBsAg positive at baseline, 3/70 (4.3%) achieved seroconversion to anti-HBs Week 48. 
Med bolniki, ki so bili ob izhodišču HBsAg pozitivni, so 3/70 (4,3 %) dosegli serokonverzijo na anti-HBs v 48. tednu.
Table 1: Dose of Descovy according to third agent in the HIV treatment regimen 
Preglednica 1: Odmerek zdravila Descovy glede na tretjo učinkovino v režimu zdravljenja HIV Odmerek zdravila Descovy Tretje zdravilo v režimu zdravljenja HIV
Following administration of food in healthy subjects, peak plasma concentrations were observed approximately 1 hour post-dose for tenofovir alafenamide administered as F/TAF (25 mg) or E/C/F/TAF (10 mg). 
Po dajanju hrane zdravim prostovoljcem so najvišje plazemske koncentracije opazili približno 1 uro po odmerku tenofoviralafenamida, uporabljenega kot F/TAF (25 mg) ali E/C/F/TAF (10 mg).
In a study of virologically suppressed adult patients switching from abacavir/lamivudine to Descovy while maintaining the third antiretroviral agent (Study GS-US-311-1717), there were minimal changes in lipid parameters. 
V študiji pri odraslih bolnikih z virološko supresijo, ki so prešli z abakavirja/lamivudina na zdravilo Descovy, pri čemer so obdržali tretje protiretrovirusno zdravilo (študija GS-US-311-1717), so opazili minimalne spremembe v parametrih lipidov.
A minimal infiltration of histiocytes was present in the eye in dogs at tenofovir alafenamide and tenofovir exposures of approximately 4 and 17 times greater, respectively, than those expected after administration of Descovy. 
Minimalna infiltracija histiocitov je bila prisotna v očesu psov pri izpostavljenosti tenofoviralafenamidu in tenofovirju, ki je bila približno 4-krat oz. 17-krat večja od pričakovane po dajanju zdravila Descovy.
Do not stop taking Descovy 
Ne prenehajte jemati zdravila Descovy